RE:RE:ONCY's pelareorep enables CAR-T trafficking in solid tumorsOn March 15, the FDA’s Oncologic Drugs Advisory Committee will meet to discuss two CAR T cell therapies for multiple myeloma.
“At a high level, this will be an interesting meeting for the CAR-T field as the industry looks to understand how the FDA is thinking about moving these treatments into earlier-line settings,”
The survival benefit is not the most important measure of the CAR-T success. While patients may not necessarily live longer, “what we do see is that [they] get a substantial benefit, remission and better quality of life across the board.” Rahul Banerjee, a physician-researcher specializing in multiple myeloma at the Fred Hutchinson Cancer Center in Seattle, Wash. pointed to the concept of time toxicity in myeloma, where patients in the control arm receiving standard-of-care treatment need to travel to and spend time in the clinic repeatedly in order to receive treatment.
https://www.biospace.com/article/odac-adcomm-to-tackle-complexity-of-car-t-in-multiple-myeloma/